PUBLISHER: Grand View Research | PRODUCT CODE: 1986312
PUBLISHER: Grand View Research | PRODUCT CODE: 1986312
The global clinical trial third party logistics market size was estimated at USD 3.13 billion in 2025 and is projected to reach USD 5.93 billion by 2033, growing at a CAGR of 8.51% from 2026 to 2033. The growing globalization of clinical research, rising number of ongoing and planned clinical trials, and increasing R&D spending by pharmaceutical and biopharmaceutical companies are key factors expected to support market expansion.
In addition, ongoing advancements in supply chain technologies are enhancing operational efficiency, transparency, and reliability across clinical trial logistics. The increasing complexity of study designs, including multi-regional, decentralized, and advanced therapy trials, is further driving the adoption of digital tracking, real-time monitoring, and data-driven logistics solutions to enable faster, more compliant, and cost-effective clinical trial execution.
The clinical trial 3PL market is experiencing strong growth due to the rising adoption of precision medicine, biologics, and decentralized clinical trial models, which have significantly increased the need for specialized outsourced logistics services. Advanced therapies require stringent temperature control, customized packaging, secure transportation, and real-time monitoring to maintain product integrity and regulatory compliance across global trial sites. As a result, pharmaceutical and biotechnology companies are increasingly relying on third-party logistics providers to manage complex distribution networks, cold chain requirements, and global site coordination, thereby supporting market expansion.
In addition, the growing complexity of multi-regional trials, expansion into emerging markets, and increasing regulatory scrutiny are accelerating the shift toward outsourced logistics models. Sponsors are focusing on core drug development activities while leveraging the expertise of 3PL providers in areas such as inventory management, risk mitigation, demand forecasting, and last-mile delivery. The integration of digital tracking platforms, IoT-enabled temperature monitoring, and just-in-time supply strategies is further enhancing operational efficiency and visibility across the clinical trial logistics ecosystem. Strategic partnerships and service expansion initiatives are also enabling logistics providers to broaden their global reach and strengthen service portfolios.
Furthermore, increasing R&D investments and the expanding pipeline of biologics, cell and gene therapies, and specialty injectables are expected to drive sustained demand for outsourced clinical trial logistics. Pharmaceutical and biotechnology companies are investing in global trial expansion and patient-centric approaches, which require flexible, scalable, and compliant logistics networks. Leading providers such as DHL and UPS Healthcare continue to expand temperature-controlled infrastructure, digital capabilities, and regional distribution hubs to address evolving sponsor requirements, reinforcing the long-term growth outlook of the clinical trial third party logistics industry.
Global Clinical Trial Third Party Logistics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the clinical trial third party logistics market report based on service, phase, therapeutic area, end use, and region: